Correlation of genetic variations with use of remifentanil as the analgesic during elective thyroid gland surgery

Phase 4

Completed

• Conditions: thyroidectomy; Anaesthesiology - Pain management

• Registration Number: ACTRN12616001598471
• Lead Sponsor: Aristotle University of Thessaloniki, Greece

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-18
• Study Completion: 2019-12-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients aged 18-79 years,
Preoperative ASA 1-2,
Normal levels of thyroid hormones
Elective thyroidectomy operation
Informed consent for enrollment given

Exclusion Criteria

Patients aged <18 and> 80 years, ranking in ASA> 3, with a history of chronic pain and / or systemic use of analgesics drugs before surgery, surgical operation non elective (emergency), severe disruption of thyroid hormone levels, pregnancy, neuropsychiatric disorders.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation of the total requirements for remifentanil (n/kg/h) (assessed using TCI infusion pump indications and the total duration of the surgery) with SLC01A2 and ABCB1 gene polymorphisms (assessed by serum assay).<br>Remifentanil total requirements will be assessed using the TCI infusion pump indications and the total duration of the surgery[One hour after the patients will recover from anesthesia]